A long-acting injectable formulation of cabotegravir, Apretude could result in greater patient adherence to therapy, ViiV claims. The product will be priced at $3,700 per vial.
ViiV will become the second company into HIV PrEP with approval of Apretude
ViiV Healthcare will enter the HIV pre-exposure prophylaxis (PrEP) market in early 2022 thanks to the US Food and Drug Administration’s approval of a long-acting injectable formulation of cabotegravir, creating direct competition for Gilead Sciences, Inc. in the PrEP space with a differentiated product that ViiV said can improve patient adherence to therapy.
[Sidebar#SC145490]
Keep up with the top pharma business news of the week. On the go.
The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.
The nod will help unlock a national market for the partners’ Dupert (fulzerasib) in which roughly 50,000 people are expected to be newly diagnosed with lung cancer harboring the KRAS G12C mutation in 2025. Meanwhile, two other homegrown rivals are also closing in on marketing clearances in China.
Tarsus Pharmaceuticals is putting more sales and marketing heft behind its novel eyelid disease therapy, Xdemvy, to capitalize on a solid start in a previously untapped market.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.